腰痛(Low Back Pain):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Low Back Pain - Pipeline Review, H2 2014
◆商品コード:GMDHC5692IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月18日
◆ページ数:97
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における腰痛(Low Back Pain)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・腰痛(Low Back Pain)の概要
・腰痛(Low Back Pain)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・腰痛(Low Back Pain)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・腰痛(Low Back Pain)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・腰痛(Low Back Pain)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Low Back Pain – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Low Back Pain – Pipeline Review, H2 2014’, provides an overview of the Low Back Pain’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Low Back Pain and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Low Back Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Low Back Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Low Back Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Low Back Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Low Back Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Low Back Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Low Back Pain Overview 8
Therapeutics Development 9
Pipeline Products for Low Back Pain – Overview 9
Pipeline Products for Low Back Pain – Comparative Analysis 10
Low Back Pain – Therapeutics under Development by Companies 11
Low Back Pain – Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Low Back Pain – Products under Development by Companies 16
Low Back Pain – Companies Involved in Therapeutics Development 17
Aestus Therapeutics, Inc. 17
Astellas Pharma Inc. 18
Collegium Pharmaceutical, Inc. 19
Eisai Co., Ltd. 20
Eli Lilly and Company 21
Endo Pharmaceuticals Inc. 22
GlobalAcorn 23
Grunenthal GmbH 24
Ipsen S.A. 25
MEDRx Co., Ltd. 26
Merck & Co., Inc. 27
Mesoblast Limited 28
Paladin Labs Inc. 29
Pfizer Inc. 30
Purdue Pharma L.P. 31
Teikoku Pharma USA, Inc. 32
Teva Pharmaceutical Industries Limited 33
Low Back Pain – Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Combination Products 35
Assessment by Target 36
Assessment by Mechanism of Action 38
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
(acetaminophen + tramadol hydrochloride) – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
(diclofenac sodium + eperisone) – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
(etodolac + lidocaine) – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
(etoricoxib + tizanidine) – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
(oxycodone hydrochloride + naltrexone) ER – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
abobotulinumtoxin A – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
ASP-7962 – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Atx09-002 – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
buprenorphine hydrochloride – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
cebranopadol – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
duloxetine hydrochloride DR – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
eperisone – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
flurbiprofen – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
GA-8SMOL-PAIN – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
hydrocodone bitartrate ER – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
hydrocodone bitartrate ER – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
MPC-06-ID – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
oxycodone hydrochloride ER – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
PF-06372865 – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Low Back Pain – Recent Pipeline Updates 71
Low Back Pain – Dormant Projects 84
Low Back Pain – Discontinued Products 85
Low Back Pain – Product Development Milestones 86
Featured News & Press Releases 86
Apr 30, 2014: Purdue Pharma Submits NDA For Once-Daily Hydrocodone Bitartrate Extended-Release Tablets Formulated To Incorporate Abuse-Deterrent Properties 86
Apr 30, 2014: Teva Pharmaceutical Reports Positive Results From Pivotal Phase 3 Study To Evaluate Hydrocodone Bitartrate Extended-Release Tablets For Moderate To Severe Chronic Low Back Pain 88
Apr 02, 2014: Collegium Pharmaceutical Announces Positive Topline Results of Clinical Study Evaluating the Effect of Crushing Oxycodone DETERx Compared with OxyContin 89
Mar 19, 2014: Collegium Pharmaceutical Announces Allowance of New Claims Covering DETERx, an Abuse-Deterrent, Extended-Release, Technology Platform 90
Mar 12, 2014: Purdue Pharma L.P. Announces Positive Phase 3 Clinical Trial Results of Once-Daily Hydrocodone Bitartrate Extended-Release Tablets 90
Feb 04, 2014: Collegium Pharmaceutical Announces Completion of Enrollment in Pivotal Phase 3 Clinical Study for Oxycodone DETERx, its Lead Abuse-Deterrent Development Program 91
Jan 23, 2014: Pfizer Reports Top-Line Results From ALO-02 Phase 3 Study 92
Oct 17, 2013: Collegium Pharmaceutical Announces Issuance of U.S. Patent and Allowance of New Claims Covering Oxycodone DETERx, an Abuse-Deterrent, Extended-Release Opioid Product 93
Apr 22, 2013: Mesoblast Reports Positive Interim Results In Phase II Trial Of Adult Stem Cells For Intervertebral Disc Repair 93
Oct 18, 2012: Collegium Pharma Announces Poster Presentation On Oxycodone DETERx At 2012 American Association Of Pharmaceutical Scientists Annual Meeting 94
Appendix 96
Methodology 96
Coverage 96
Secondary Research 96
Primary Research 96
Expert Panel Validation 96
Contact Us 97
Disclaimer 97

[List of Tables]
Number of Products under Development for Low Back Pain, H2 2014 9
Number of Products under Development for Low Back Pain - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Low Back Pain - Pipeline by Aestus Therapeutics, Inc., H2 2014 17
Low Back Pain - Pipeline by Astellas Pharma Inc., H2 2014 18
Low Back Pain - Pipeline by Collegium Pharmaceutical, Inc., H2 2014 19
Low Back Pain - Pipeline by Eisai Co., Ltd., H2 2014 20
Low Back Pain - Pipeline by Eli Lilly and Company, H2 2014 21
Low Back Pain - Pipeline by Endo Pharmaceuticals Inc., H2 2014 22
Low Back Pain - Pipeline by GlobalAcorn, H2 2014 23
Low Back Pain - Pipeline by Grunenthal GmbH, H2 2014 24
Low Back Pain - Pipeline by Ipsen S.A., H2 2014 25
Low Back Pain - Pipeline by MEDRx Co., Ltd., H2 2014 26
Low Back Pain - Pipeline by Merck & Co., Inc., H2 2014 27
Low Back Pain - Pipeline by Mesoblast Limited, H2 2014 28
Low Back Pain - Pipeline by Paladin Labs Inc., H2 2014 29
Low Back Pain - Pipeline by Pfizer Inc., H2 2014 30
Low Back Pain - Pipeline by Purdue Pharma L.P., H2 2014 31
Low Back Pain - Pipeline by Teikoku Pharma USA, Inc., H2 2014 32
Low Back Pain - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 33
Assessment by Monotherapy Products, H2 2014 34
Assessment by Combination Products, H2 2014 35
Number of Products by Stage and Target, H2 2014 37
Number of Products by Stage and Mechanism of Action, H2 2014 39
Number of Products by Stage and Route of Administration, H2 2014 41
Number of Products by Stage and Molecule Type, H2 2014 43
Low Back Pain Therapeutics - Recent Pipeline Updates, H2 2014 71
Low Back Pain - Dormant Projects, H2 2014 84
Low Back Pain - Discontinued Products, H2 2014 85

[List of Figures]
Number of Products under Development for Low Back Pain, H2 2014 9
Number of Products under Development for Low Back Pain - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Assessment by Monotherapy Products, H2 2014 34
Number of Products by Top 10 Targets, H2 2014 36
Number of Products by Stage and Top 10 Targets, H2 2014 36
Number of Products by Top 10 Mechanism of Actions, H2 2014 38
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 38
Number of Products by Top 10 Routes of Administration, H2 2014 40
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 41
Number of Products by Top 10 Molecule Types, H2 2014 42
Number of Products by Stage and Top 10 Molecule Types, H2 2014 43

【掲載企業】

Aestus Therapeutics, Inc.
Astellas Pharma Inc.
Collegium Pharmaceutical, Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Endo Pharmaceuticals Inc.
GlobalAcorn
Grunenthal GmbH
Ipsen S.A.
MEDRx Co., Ltd.
Merck & Co., Inc.
Mesoblast Limited
Paladin Labs Inc.
Pfizer Inc.
Purdue Pharma L.P.
Teikoku Pharma USA, Inc.
Teva Pharmaceutical Industries Limited

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[腰痛(Low Back Pain):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆